Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia.

Induction of apoptosis with the combination of nilotinib plus IB was clearly markedly enhanced with respect to either drug as a single agent (representative example in Figure 3A ) although this did not reach statistical significance owing to inter-patient variability in extent of response.

also in 111,027 other papers